A Decade of Progress in Regional ST-Segment Elevation Myocardial Infarction Systems of Care: A Tale of Two Cities
David C. Lange, MD, Ivan C. Rokos, MD, David C. Larson, MD, Scott W. Sharkey, MD, William J. French, MD, William J. Koenig, MD, Timothy D. Henry, MD
The advent of regional ST-segment elevation myocardial infarction (STEMI) systems of care has decreased the number of “eligible but untreated” patients while improving access to primary percutaneous coronary intervention for patients. These regional STEMI systems of care have consistently demonstrated that rapid transport of STEMI patients is safe and effective, and have shown marked improvements in a variety of clinical outcomes. However, no two STEMI systems are alike, and each must be tailored to the unique geographical, political, and socioeconomic challenges of the region. This article takes an in-depth look at two of the earliest STEMI systems within the United States: the Minneapolis Heart Institute and the Los Angeles County STEMI receiving network.
A Closer Look at Fractional Flow Reserve in Complex Anatomic Subsets: Left Main Disease, Bifurcation Lesions, and Saphenous Vein Grafts
David C. Lange, MD, Morton J. Kern, MD
Fractional flow reserve (FFR) is a well-validated tool for determining the functional significance of a coronary artery stenosis, facilitating clinical decisions regarding the need for revascularization. FFR-guided revascularization improves clinical and economic outcomes. However, its application remains challenging in certain complex anatomic subsets, including left main coronary artery stenosis, bifurcation disease, and saphenous vein graft disease. This article reviews recent data supporting the use of FFR in these complex anatomic subsets.
Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Daniel Soffer, MD, FNLA, FACP, P. Barton Duell, MD, FAHA, FNLA
In patients with homozygous familial hypercholesterolemia (HoFH), the standard drug regimen of statins, ezetimibe, and bile acid sequestrants does not adequately lower low-density lipoprotein (LDL) cholesterol, frequently requiring concurrent LDL cholesterol apheresis to reduce lipid levels sufficiently. Drug development is being approached on several fronts for HoFH (eg, MTP inhibitors, RNA-based drugs, monoclonal antibodies) and is encouraging, but there is a gap between the age group needing treatment and those of the study cohorts in clinical trials. This article focuses on the clinical management of HoFH.
The Role of Medical Therapy in Moderate to Severe Degenerative Mitral Regurgitation
Leandro Slipczuk, MD, PhD, Asim M. Rafique, MD, Carlos D. Davila, MD, Roy Beigel, MD, Gregg S. Pressman, MD, Robert J. Siegel, MD
The authors review the available published data on medical therapy in the treatment of patients with primary mitral regurgitation.
A Review of the Clinical Subgroup Analyses From the RE-LY Trial
Rohit Kumar, MD, Aref M. Rahman, MD, Brian L. Henry, MD, PhD
Understanding the differences in outcomes between specific patient subgroups from the RE-LY trial can better inform the practicing clinician’s ability to offer the best anticoagulation options to individual patients.
Cardiovascular Effects of Altitude on Performance Athletes
Ankit B. Shah, MD, MPH, Neil Coplan, MD, FACC
Further research is needed on the long-term effects of altitude training, as repeated, transient episodes of pulmonary hypertension and right ventricular dysfunction may have long-term implications. Current literature suggests that performance athletes are not at higher risk for ventricular arrhythmias when training or competing at increased altitudes. For sea-level athletes, the optimal strategy for attaining the benefits while minimizing the harms of altitude training still needs to be clarified, although—for now—the “live high, train low” approach appears to have the most rationale.
The Role of Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy
Marco Marchesini, MD, Lucia Uguccioni, MD, Rosario Parisi, MD, Gianmaria Mattioli, MD, Francesca Terzi, MD, Roberto Olivieri, MD, Alessandro Capucci, MD, Rossella Fattori, MD
Cardiac magnetic resonance imaging has gained an essential role in the diagnosis of hypertrophic cardiomyopathy, offering an important advantage in the understanding of pathologic mechanisms of the disease, allowing early identification, risk stratification, and timely therapeutic management.
An Update From the California Chapter of the American College of Cardiology Board of Directors
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Leading the Way: Cardiology and the Future of HealthTech Innovation
Seema Pursnani, MD, MPH, FACC, Raj Khandwalla, MD, Rigved Tadwalkar, MD, MS
Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging
Emily Tat, Richard Cheng, MD, Jeffrey S. Helfenstein, MD
The authors report on a case of a 48-year-old woman with 40 years of intermittent squeezing chest pain presenting with worsening symptoms.
Vascular Complications of Percutaneous Transradial Cardiac Catheterization
Manish Patwardhan, MD, Sanjay Mehra, MD, Assad Movahed, MD, Ramesh Daggubati, MD
The authors present two cases of vascular complications, pseudoaneurysm and radial artery occlusion, after transradial cardiac catheterization, along with a review of the relevant literature.
Isolated Left Ventricular Noncompaction Cardiomyopathy: A Transient Disease?
Juan M. Vinardell, MD, Maria D. Avila, MD, Orlando Santana, MD
solated left ventricular noncompaction is either a distinct cardiomyopathy or a morphologic trait shared by several different types of cardiomyopathies. Although there is no current gold standard for its diagnosis, cardiac imaging is the most commonly accepted modality. Described is a case of left ventricular noncompaction that resolved 2 years after the initial diagnosis.
Now available for your iPhone and iPad
A Decade of Progress in Regional ST-Segment Elevation Myocardial Infarction Systems of Care: A Tale of Two Cities
David C. Lange, MD, Ivan C. Rokos, MD, David C. Larson, MD, Scott W. Sharkey, MD, William J. French, MD, William J. Koenig, MD, Timothy D. Henry, MD
The advent of regional ST-segment elevation myocardial infarction (STEMI) systems of care has decreased the number of “eligible but untreated” patients while improving access to primary percutaneous coronary intervention for patients. These regional STEMI systems of care have consistently demonstrated that rapid transport of STEMI patients is safe and effective, and have shown marked improvements in a variety of clinical outcomes. However, no two STEMI systems are alike, and each must be tailored to the unique geographical, political, and socioeconomic challenges of the region. This article takes an in-depth look at two of the earliest STEMI systems within the United States: the Minneapolis Heart Institute and the Los Angeles County STEMI receiving network.
A Closer Look at Fractional Flow Reserve in Complex Anatomic Subsets: Left Main Disease, Bifurcation Lesions, and Saphenous Vein Grafts
David C. Lange, MD, Morton J. Kern, MD
Fractional flow reserve (FFR) is a well-validated tool for determining the functional significance of a coronary artery stenosis, facilitating clinical decisions regarding the need for revascularization. FFR-guided revascularization improves clinical and economic outcomes. However, its application remains challenging in certain complex anatomic subsets, including left main coronary artery stenosis, bifurcation disease, and saphenous vein graft disease. This article reviews recent data supporting the use of FFR in these complex anatomic subsets.
Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Daniel Soffer, MD, FNLA, FACP, P. Barton Duell, MD, FAHA, FNLA
In patients with homozygous familial hypercholesterolemia (HoFH), the standard drug regimen of statins, ezetimibe, and bile acid sequestrants does not adequately lower low-density lipoprotein (LDL) cholesterol, frequently requiring concurrent LDL cholesterol apheresis to reduce lipid levels sufficiently. Drug development is being approached on several fronts for HoFH (eg, MTP inhibitors, RNA-based drugs, monoclonal antibodies) and is encouraging, but there is a gap between the age group needing treatment and those of the study cohorts in clinical trials. This article focuses on the clinical management of HoFH.
The Role of Medical Therapy in Moderate to Severe Degenerative Mitral Regurgitation
Leandro Slipczuk, MD, PhD, Asim M. Rafique, MD, Carlos D. Davila, MD, Roy Beigel, MD, Gregg S. Pressman, MD, Robert J. Siegel, MD
The authors review the available published data on medical therapy in the treatment of patients with primary mitral regurgitation.
A Review of the Clinical Subgroup Analyses From the RE-LY Trial
Rohit Kumar, MD, Aref M. Rahman, MD, Brian L. Henry, MD, PhD
Understanding the differences in outcomes between specific patient subgroups from the RE-LY trial can better inform the practicing clinician’s ability to offer the best anticoagulation options to individual patients.
Cardiovascular Effects of Altitude on Performance Athletes
Ankit B. Shah, MD, MPH, Neil Coplan, MD, FACC
Further research is needed on the long-term effects of altitude training, as repeated, transient episodes of pulmonary hypertension and right ventricular dysfunction may have long-term implications. Current literature suggests that performance athletes are not at higher risk for ventricular arrhythmias when training or competing at increased altitudes. For sea-level athletes, the optimal strategy for attaining the benefits while minimizing the harms of altitude training still needs to be clarified, although—for now—the “live high, train low” approach appears to have the most rationale.
The Role of Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy
Marco Marchesini, MD, Lucia Uguccioni, MD, Rosario Parisi, MD, Gianmaria Mattioli, MD, Francesca Terzi, MD, Roberto Olivieri, MD, Alessandro Capucci, MD, Rossella Fattori, MD
Cardiac magnetic resonance imaging has gained an essential role in the diagnosis of hypertrophic cardiomyopathy, offering an important advantage in the understanding of pathologic mechanisms of the disease, allowing early identification, risk stratification, and timely therapeutic management.
An Update From the California Chapter of the American College of Cardiology Board of Directors
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Leading the Way: Cardiology and the Future of HealthTech Innovation
Seema Pursnani, MD, MPH, FACC, Raj Khandwalla, MD, Rigved Tadwalkar, MD, MS
Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging
Emily Tat, Richard Cheng, MD, Jeffrey S. Helfenstein, MD
The authors report on a case of a 48-year-old woman with 40 years of intermittent squeezing chest pain presenting with worsening symptoms.
Vascular Complications of Percutaneous Transradial Cardiac Catheterization
Manish Patwardhan, MD, Sanjay Mehra, MD, Assad Movahed, MD, Ramesh Daggubati, MD
The authors present two cases of vascular complications, pseudoaneurysm and radial artery occlusion, after transradial cardiac catheterization, along with a review of the relevant literature.
Isolated Left Ventricular Noncompaction Cardiomyopathy: A Transient Disease?
Juan M. Vinardell, MD, Maria D. Avila, MD, Orlando Santana, MD
solated left ventricular noncompaction is either a distinct cardiomyopathy or a morphologic trait shared by several different types of cardiomyopathies. Although there is no current gold standard for its diagnosis, cardiac imaging is the most commonly accepted modality. Described is a case of left ventricular noncompaction that resolved 2 years after the initial diagnosis.
Now available for your iPhone and iPad
A Decade of Progress in Regional ST-Segment Elevation Myocardial Infarction Systems of Care: A Tale of Two Cities
David C. Lange, MD, Ivan C. Rokos, MD, David C. Larson, MD, Scott W. Sharkey, MD, William J. French, MD, William J. Koenig, MD, Timothy D. Henry, MD
The advent of regional ST-segment elevation myocardial infarction (STEMI) systems of care has decreased the number of “eligible but untreated” patients while improving access to primary percutaneous coronary intervention for patients. These regional STEMI systems of care have consistently demonstrated that rapid transport of STEMI patients is safe and effective, and have shown marked improvements in a variety of clinical outcomes. However, no two STEMI systems are alike, and each must be tailored to the unique geographical, political, and socioeconomic challenges of the region. This article takes an in-depth look at two of the earliest STEMI systems within the United States: the Minneapolis Heart Institute and the Los Angeles County STEMI receiving network.
A Closer Look at Fractional Flow Reserve in Complex Anatomic Subsets: Left Main Disease, Bifurcation Lesions, and Saphenous Vein Grafts
David C. Lange, MD, Morton J. Kern, MD
Fractional flow reserve (FFR) is a well-validated tool for determining the functional significance of a coronary artery stenosis, facilitating clinical decisions regarding the need for revascularization. FFR-guided revascularization improves clinical and economic outcomes. However, its application remains challenging in certain complex anatomic subsets, including left main coronary artery stenosis, bifurcation disease, and saphenous vein graft disease. This article reviews recent data supporting the use of FFR in these complex anatomic subsets.
Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Daniel Soffer, MD, FNLA, FACP, P. Barton Duell, MD, FAHA, FNLA
In patients with homozygous familial hypercholesterolemia (HoFH), the standard drug regimen of statins, ezetimibe, and bile acid sequestrants does not adequately lower low-density lipoprotein (LDL) cholesterol, frequently requiring concurrent LDL cholesterol apheresis to reduce lipid levels sufficiently. Drug development is being approached on several fronts for HoFH (eg, MTP inhibitors, RNA-based drugs, monoclonal antibodies) and is encouraging, but there is a gap between the age group needing treatment and those of the study cohorts in clinical trials. This article focuses on the clinical management of HoFH.
The Role of Medical Therapy in Moderate to Severe Degenerative Mitral Regurgitation
Leandro Slipczuk, MD, PhD, Asim M. Rafique, MD, Carlos D. Davila, MD, Roy Beigel, MD, Gregg S. Pressman, MD, Robert J. Siegel, MD
The authors review the available published data on medical therapy in the treatment of patients with primary mitral regurgitation.
A Review of the Clinical Subgroup Analyses From the RE-LY Trial
Rohit Kumar, MD, Aref M. Rahman, MD, Brian L. Henry, MD, PhD
Understanding the differences in outcomes between specific patient subgroups from the RE-LY trial can better inform the practicing clinician’s ability to offer the best anticoagulation options to individual patients.
Cardiovascular Effects of Altitude on Performance Athletes
Ankit B. Shah, MD, MPH, Neil Coplan, MD, FACC
Further research is needed on the long-term effects of altitude training, as repeated, transient episodes of pulmonary hypertension and right ventricular dysfunction may have long-term implications. Current literature suggests that performance athletes are not at higher risk for ventricular arrhythmias when training or competing at increased altitudes. For sea-level athletes, the optimal strategy for attaining the benefits while minimizing the harms of altitude training still needs to be clarified, although—for now—the “live high, train low” approach appears to have the most rationale.
The Role of Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy
Marco Marchesini, MD, Lucia Uguccioni, MD, Rosario Parisi, MD, Gianmaria Mattioli, MD, Francesca Terzi, MD, Roberto Olivieri, MD, Alessandro Capucci, MD, Rossella Fattori, MD
Cardiac magnetic resonance imaging has gained an essential role in the diagnosis of hypertrophic cardiomyopathy, offering an important advantage in the understanding of pathologic mechanisms of the disease, allowing early identification, risk stratification, and timely therapeutic management.
An Update From the California Chapter of the American College of Cardiology Board of Directors
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Leading the Way: Cardiology and the Future of HealthTech Innovation
Seema Pursnani, MD, MPH, FACC, Raj Khandwalla, MD, Rigved Tadwalkar, MD, MS
Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging
Emily Tat, Richard Cheng, MD, Jeffrey S. Helfenstein, MD
The authors report on a case of a 48-year-old woman with 40 years of intermittent squeezing chest pain presenting with worsening symptoms.
Vascular Complications of Percutaneous Transradial Cardiac Catheterization
Manish Patwardhan, MD, Sanjay Mehra, MD, Assad Movahed, MD, Ramesh Daggubati, MD
The authors present two cases of vascular complications, pseudoaneurysm and radial artery occlusion, after transradial cardiac catheterization, along with a review of the relevant literature.
Isolated Left Ventricular Noncompaction Cardiomyopathy: A Transient Disease?
Juan M. Vinardell, MD, Maria D. Avila, MD, Orlando Santana, MD
solated left ventricular noncompaction is either a distinct cardiomyopathy or a morphologic trait shared by several different types of cardiomyopathies. Although there is no current gold standard for its diagnosis, cardiac imaging is the most commonly accepted modality. Described is a case of left ventricular noncompaction that resolved 2 years after the initial diagnosis.
Now available for your iPhone and iPad